retatrutide weight loss clinical data Lilly's shows 28% loss, but increased side effects Retatrutide for weight loss: Study

and reduced risk of MACEs, cardiovascular mortality, and HF hospitalization in high-cardiovascular-risk T2D patients [2,99,100]

DOI: Published online: May 1, 2025 1 Department of Medicine, Seoul National University College of Medicine, Seoul, Korea 2 Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea 3 Department of Anatomy and Cell Biology, Seoul National University College of Medicine, Seoul, Korea 4 Neuroscience Research Institute, Seoul National University College of Medicine, Seoul, Korea 5 Wide River Institute of Immunology, Seoul National University, Hongcheon, Korea 6 Department of Brain and Cognitive Sciences, Seoul National University, Seoul, Korea Corresponding author: Hyung Jin Choi Department of Medicine, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul 03080, Korea E-mail: [email protected] Copyright 2025 Korean Diabetes Association This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited

However, remember that semaglutide has a 7-day half-life

The weight loss drug might ensure even more weight loss if the administration of Retatrutide was longer than anticipated

Best features include: Barcode scanning for accuracy Photo recognition of meals Easy portion size adjustments Side Effect Tracking GLP-1 medications can cause nausea, constipation, or other side effects